Back to Search
Start Over
Safe Administration of Cemiplimab to a Kidney Transplant Patient with Locally Advanced Squamous Cell Carcinoma of the Scalp
- Source :
- Current Oncology, Current Oncology, Vol 28, Iss 57, Pp 574-580 (2021)
- Publication Year :
- 2021
- Publisher :
- MDPI, 2021.
-
Abstract
- Immunotherapies directed at T-cell activation through antibodies targeting checkpoint proteins, such as programmed cell death 1 (PD1), are rapidly becoming the new standard of care in the treatment of several malignancies. Cemiplimab is a monoclonal antibody targeting PD1 that has recently emerged as a highly active treatment for locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC). Patients who have received an organ transplant (OTRs) have been traditionally excluded from clinical trials with checkpoint inhibitors (CIs), given concerns for organ rejection. Renal transplant recipients (RTRs) are more likely to develop cancers than the general population, and skin cancers are among the most frequent malignancies. We report the case of a 72-year-old man with a history of a kidney transplant who presented with a rapidly growing, locally advanced squamous cell carcinoma (SCC) of the scalp that recurred within four weeks from surgical resection. The patient was able to safely receive ten cycles of cemiplimab so far with significant clinical benefit, and no issues with his kidney function, while continuing immunosuppression with low dose prednisone alone. An ongoing clinical trial (NCT04339062) is further exploring the safety of CIs in patients with metastatic CSCC who have previously received allogeneic hematopoietic stem cell transplant or a kidney transplant.
- Subjects :
- 0301 basic medicine
Oncology
kidney transplant
medicine.medical_specialty
cutaneous squamous cell carcinoma
medicine.medical_treatment
Population
Renal function
Case Report
Organ transplantation
03 medical and health sciences
0302 clinical medicine
Prednisone
Internal medicine
medicine
education
Kidney transplantation
RC254-282
education.field_of_study
business.industry
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Immunosuppression
medicine.disease
Clinical trial
PD1
030104 developmental biology
medicine.anatomical_structure
checkpoint inhibitor
030220 oncology & carcinogenesis
Scalp
cemiplimab
business
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 17187729 and 11980052
- Volume :
- 28
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- Current Oncology
- Accession number :
- edsair.doi.dedup.....c2a879b9c401a46db27bb2bff12f5b5e